Themed collection Editor’s Choice Collection


Antimicrobial triazinedione inhibitors of the translocase MraY–protein E interaction site: synergistic effects with bacitracin imply a new mechanism of action
A set of triazinedione peptidomimetics of an Arg-Trp-x-x-Trp motif found in MraY were found to show antimicrobial activity against antibiotic-resistant clinical isolates, via a novel mechanism of action.
RSC Med. Chem., 2025,16, 1641-1653
https://doi.org/10.1039/D4MD00937A

Design and synthesis of cyclic lipidated peptides derived from the C-terminus of Cx43 for hemichannel inhibition and cardiac endothelium targeting
Potent and stable cyclic peptide inhibitors of Cx43 were identified. Their therapeutic potential was enhanced by the addition of a lipid motif (preserving water solubility), and a targeting peptide, for delivery to cardiac endothelial cells.
RSC Med. Chem., 2025,16, 1289-1303
https://doi.org/10.1039/D4MD00850B

Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells through inhibition of Wnt/β-catenin signaling
We designed and synthesized novel IOX1-based PROTACs, which can selectively degrade KDM3A and KDM3B to eliminate colorectal cancer stem cells through inhibition of Wnt signaling.
RSC Med. Chem., 2024,15, 3746-3758
https://doi.org/10.1039/D4MD00122B

Identification of lysosomotropism using explainable machine learning and morphological profiling cell painting data
Explainable ML was used to identify important chemical structural properties that contribute to lysosomotropism.
RSC Med. Chem., 2024,15, 2677-2691
https://doi.org/10.1039/D4MD00107A

Live cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7–Lin28 RNA–protein interaction
Dysregulation of the networking of RNA-binding proteins (RBPs) and RNAs drives many human diseases, including cancers, and the targeting of RNA–protein interactions (RPIs) has emerged as an exciting area of RNA-targeted drug discovery.
RSC Med. Chem., 2024,15, 1539-1546
https://doi.org/10.1039/D4MD00123K

1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists
Utilizing a combination of structure-based design, MCR synthesis, biophysics, and protein crystallography to innovate a novel tetrazole scaffold targeting the PD-1/PD-L1 immune checkpoint protein complex.
RSC Med. Chem., 2024,15, 1210-1215
https://doi.org/10.1039/D3MD00746D